Goals

  • Finding early diagnostic indicators that can accurately identify patients with localized tumors who benefit from (minimally invasive) treatment while avoiding unnecessary biopsies and treatment;
  • Developing and evaluating new treatment and diagnostic modalities with better efficacy and less mutilating effects;
  • Finding pre- and on-treatment biomarkers that can identify or early discriminate patients  who are expected to respond to specific therapies;
  • Identifying host–related risk factors as leads for primary and tertiary prevention;
  • Optimize the risk-benefit ratio of available anticancer drugs through early identify.


go to main content
Research Research programs Prostate, bladder and kidney cancer

Our purpose

We aim to solve the diagnostic and treatment dilemmas for prostate, bladder and kidney cancer.

Goals

See some of the most important goals for this research program.

read more

Research groups contributing to this research program

Biomedical magnetic resonance

Tom Scheenen's research group develops, implement, and test new MR imaging and spectroscopy technology at clinical and ultra-high magnetic field MR scanners. 

Epidemiology

Bart Kiemeney's research group aims to improve the diagnosis and treatment of urological cancers using observational and experimental designs.

Nuclear imaging and therapy in immuno-oncology

Sandra Heskamp's research group develops novel radiopharmaceuticals to visualize and treat cancer.

Spokesperson(s) for this research program

Spokesperson

prof. dr. ir. Tom Scheenen

contact form